Jason Drew Smith - 31 Jan 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
General Counsel
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2025
Net transactions value
-$82,202
Form type
4
Filing time
04 Feb 2025, 11:51:51 UTC
Previous filing
12 Sep 2024
Next filing
30 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +2,500 +9.9% 27,726 31 Jan 2025 Direct F1
transaction URGN Ordinary Shares Sale $14,014 -1,258 -4.5% $11.14 26,468 31 Jan 2025 Direct F2
transaction URGN Ordinary Shares Options Exercise +6,667 +25% 33,135 31 Jan 2025 Direct F1
transaction URGN Ordinary Shares Sale $37,364 -3,354 -10% $11.14 29,781 31 Jan 2025 Direct F2
transaction URGN Ordinary Shares Options Exercise +5,500 +18% 35,281 31 Jan 2025 Direct F1
transaction URGN Ordinary Shares Sale $30,824 -2,767 -7.8% $11.14 32,514 31 Jan 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -2,500 -100% $0.000000 0 31 Jan 2025 Ordinary Shares 2,500 Direct F1, F3
transaction URGN Restricted Stock Units Options Exercise $0 -6,667 -50% $0.000000 6,667 31 Jan 2025 Ordinary Shares 6,667 Direct F1, F4
transaction URGN Restricted Stock Units Options Exercise $0 -5,500 -33% $0.000000 11,000 31 Jan 2025 Ordinary Shares 5,500 Direct F1, F5
transaction URGN Restricted Stock Units Award $0 +10,000 $0.000000 10,000 31 Jan 2025 Ordinary Shares 10,000 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
F4 The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
F5 The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
F6 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028.